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Bacterial vaginosis is one of the most common urogenital diseases affecting women
in reproductive age. The administration of probiotics as vaginal suppository has been
proposed as a strategy to cure this condition and reduce its recurrence. Nonetheless,
also oral consumption of probiotics, which is a more practical route of administration,
proved to be an efficient strategy. In this perspective, we studied Lactobacillus paracasei
LPC-S01 (DSM 26760), a human vaginal isolate included in commercial probiotic
preparations for topical use, in order to assess if this bacterium can also perform
as gastrointestinal probiotic. Comparative genomics revealed the presence of several
accessory genes suggesting that LPC-S01 is a niche-generalist member of its species.
According to a procedure conventionally used to predict the probiotic potential, we
demonstrated that the probiotic properties of strain LPC-S01, with respect to those
of the well-known probiotic references L. paracasei Shirota and DG, are equal for the
bile tolerance and the reduction of NF-κB activation in Caco-2 cells, or superior for
the tolerance to gastric juice and the adhesion to Caco-2 epithelial cells. We then
demonstrated that LPC-S01 is susceptible to antibiotics indicated by EFSA and does
not produce biogenic amines. Finally, a double-blind cross-over pilot intervention trial
on healthy human volunteers showed that, after a 7-days oral consumption of capsules
containing about 24 billion live cells, the fecal cell concentrations of strains LPC-S01
and DG (evaluated by qPCR) were not dissimilar. Specifically, both probiotics’ cell
concentrations were above the detection limit for an average of 5 days from the end of
the treatment, corresponding to a mean number of evacuations of 7± 2. Taken together,
these data demonstrate that the vaginal isolate L. paracasei LPC-S01 possesses safety
and functional properties that may support its use as probiotic to be administered per os
for potential intestinal as well as vaginal applications.
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Introduction
The genus Lactobacillus is a taxonomically broad and
heterogeneous group of Gram positive bacteria, which has
important industrial applications as fermented food starter and
probiotic adjuncts. Particularly, lactobacilli are the bacteria most
frequently employed as probiotics, i.e., “live microorganisms
which when administered in adequate amounts confer a health
benefit on the host” (FAO/WHO, 2002). Inside the Lactobacillus
genus, the L. casei group of species (i.e., L. casei, L. paracasei,
and L. rhamnosus) includes some of the most conventional
and well-characterized probiotic strains, such as L. paracasei
Shirota (considered the first probiotic ever; Nanno et al.,
2011), and L. rhamnosus GG (Szajewska and Chmielewska,
2013).
Strains of the L. paracasei species have been isolated from
several diverse ecological niches such as raw milk, plants,
fermented artisanal products (fermentedmilk, cheese, sourdough
bread starter, and fermented vegetables), and the intestinal
tracts and reproductive systems of humans and animals (Cai
et al., 2007). The remarkable ecological adaptability of L.
paracasei to diverse habitats can be plausibly explained by very
frequent accumulation of indels and genome rearrangements,
which originated a high level of genotypic and phenotypic
diversity in the species (Cai et al., 2007; Smokvina et al.,
2013). Given that most effects of probiotics are strain-specific
(Azaïs-Braesco et al., 2010), the intrinsic high heterogeneity
existing among L. paracasei strains makes this species an
optimal source for the selection of novel candidate probiotic
strains possessing unique technological and health-promoting
traits.
So far, lactobacilli have been predominantly investigated and
explicitly proposed as probiotics for their potential beneficial
roles on the gastrointestinal tract and itsmicrobiota (Guglielmetti
et al., 2011; Ferrario et al., 2014). Nevertheless, the interest
for the application of lactobacilli beyond the gut is constantly
increasing, leading to the development of new categories of
probiotic products that target oral cavity (Guglielmetti et al.,
2010a,b; Taverniti et al., 2012; Wescombe et al., 2012), skin
(Krutmann, 2009), stomach (Johnson-Henry et al., 2004), urinary
tract (Borchert et al., 2008), and vaginal mucosa (Borges et al.,
2014).
Interestingly, it was demonstrated that orally administered
lactobacilli can be re-isolated from the vagina, presumably as
a consequence of the migration from the rectum via perineum
(Vásquez et al., 2005). Consistently, bacteria colonizing the
vaginal mucosa (both commensals and vaginosis-associated
microbes) have been isolated from the rectum and the mouth,
suggesting that gut and oral cavity act as extravaginal reservoirs
of vaginal microbiota bacteria (van de Wijgert et al., 2014).
Therefore, it appears plausible that the oral administration
of probiotic bacteria may potentially influence the vaginal
microbiota through two possible mechanisms: (i) modification
of the intestinal microbiota (e.g., by reducing potentially
harmful bacteria and increasing endogenous lactobacilli); (ii)
direct migration to the vaginal mucosa via the gastrointestinal
route. Furthermore, the possibility to benefit vaginal health
by administering vaginal probiotics per os has the additional
advantage of favoring the accomplishment of long-term
treatments. However, in order to make this strategy effective,
selected bacteria must possess properties supporting their
survival and activities both in the gastro-intestinal tract and
vaginal mucosa. In this perspective, we assessed if L. paracasei
LPC-S01 (DSM 26760) (a strain originally isolated from the
vaginal mucosa of a healthy woman and included in probiotic
preparations for vaginal use marketed in Europe) can also
perform as a conventional gastrointestinal probiotic. To this aim,
we generated a draft genome of strain LPC-S01 and performed
a comparative genomic analysis against other L. paracasei
reference strains. In addition, we included LPC-S01 in several
in vitro tests conventionally employed to establish the intestinal
probiotic potential of microbial strains. Finally, we carried out
a double-blind cross-over pilot intervention trial in comparison
with the well-known intestinal probiotic strain L. paracasei DG
(Ferrario et al., 2014) in order to assess the ability of LPC-S01
to transiently persist in the gastrointestinal tract of healthy
adults.
Materials and Methods
Bacterial Strains and Culture Conditions
Unless differently specified, lactobacilli were grown at 37◦C in
De Man-Rogosa-Sharpe (MRS) broth (Difco Laboratories Inc.,
Detroit, MI) for 24 h. L. paracasei LPC-S01 and DG were isolated
from the commercial products PreGyn R© and Enterolactis R©
Plus (Sofar S.p.A.), respectively; L. paracasei strain Shirota was
isolated from Yakult fermented milk; strain FMBr3 was isolated
from Raschera artisanal Italian cheese.
Genome Sequencing, Sequence Annotation, and
Comparative Analysis
The draft genome sequences of L. paracasei LPC-S01, DG,
and FMBr3 were obtained through Ion Torrent PGM (Life
Technologies, Germany) according to a previously described
protocol (Milani et al., 2013) by GenProbio Ltd. The raw
sequence data were assembled using MIRA v.3.9 (http://www.
chevreux.org/projects_mira.html), applying default parameters
recommended for Ion Torrent data processing. Initial automated
annotation of the L. paracasei genomes was performed using
RAST, combined with BLASTX. Results of the gene-finder
program were combined manually with data from BLASTP
analysis against a non-redundant protein database provided by
the National Center for Biotechnology Information (NCBI).
LPC-S01 draft genome sequence was compared with other L.
paracasei genome sequences by means of BLAST Ring Image
Generator (BRIG; Alikhan et al., 2011). The DNA sequences
presented in this study have been deposited in the EMBL database
under the accession numbers LN846896 (putative phospho-β-
galactosidase operon), LN846897 (putative taurine ABC-type
transport andmetabolization operon), LN846898 (putative ABC-
type Fe3+ transport system), LN846899 (putative nucleotide
transport and metabolism operon), LN846900 (putative EPS2
region), and LN846901 (multi-transport region for the uptake of
sugars and other small molecules).
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Bacterial Resistance to Simulated Gastric Juices
and Bile
One hundred microliters of L. paracasei culture containing 108–
109 CFU/ml were transferred to 6ml of simulated gastric juice at
pH 2 (1 g/l DIFCO peptone, 100mM KCl, 500 U/ml pepsin) or
simulated gastric juice at pH 3 (125mM NaCl, 45mM NaHCO3,
7mM KCl, 500 U/ml pepsin). Cells in 0.1M phosphate buffer
pH 7 were used as control. After 90min of incubation at 37◦C,
viability was monitored by plating on MRS agar. Afterwards,
cell suspension was neutralized by adding 1M phosphate buffer
pH 8 and centrifuged at 10,000 × g for 12min. Bacterial cell
pellet was then suspended in 5ml bile solution (1 g/l peptone,
0.3% Difco Oxgall in 0.1M phosphate buffer at pH 6.5). Cells in
0.1M phosphate buffer pH 6.5 in the presence of 1 g/l peptone
were used as control. The number of viable cells was determined
after 3 h of incubation at 37◦C by plating on MRS agar. Plates
were incubated under anaerobic conditions and colonies were
counted after 48 h. The ability to grow in presence of bile was also
investigated by inoculating bacteria in MRS broth supplemented
with increasing concentrations of Oxgall (from 0.0625 to 9.6%).
Growth was assessed by measuring the optical density at 600 nm.
Bacterial Adhesion to Caco-2 Cell Line
The adhesion of L. paracasei strains to Caco-2 (ATCC HTB-
37) cell layer was assessed as previously described (Guglielmetti
et al., 2008). In brief, Caco-2 cells were grown in Dulbecco’s
Modified Eagle’s Medium (MEM) supplemented with 10% (v/v)
heat-inactivated fetal calf serum, 100 U/ml penicillin, 100mg/ml
streptomycin, 0.1mM non-essential amino acids, 2mM L-
glutamine and incubated at 37◦C in an atmosphere of 95% air and
5% carbon dioxide. For adhesion experiments, fully differentiated
Caco-2 were used (i.e., 15 days after confluence). Approximately
2×108 cells for each bacterial strain (determinedmicroscopically
with Neubauer Improved counting chamber; Marienfeld GmbH,
Lauda-Königshofen, Germany) were incubated with amonolayer
of Caco-2 cells for 1h at 37◦C. Monolayers were washed three
times with phosphate-buffered saline pH 7.3 (PBS) to release
unbound bacteria and incubated with 3ml of methanol for 8min
at room temperature to fix cells. Afterwards, cells were stained
with 3mL of Giemsa stain solution (1:20) (Carlo Erba, Milano,
Italy) and left 30min at room temperature in the dark. Finally,
monolayers were washed three times with PBS, dried in an
incubator for 1 h, and examined microscopically (magnification,
400×) under oil immersion. All experiments were performed in
duplicate.
Inhibition of Pathogens
We investigated the ability of L. paracasei strains to secret
inhibitor molecules against pathogens by disc diffusion assay.
Lactobacillus plantarum strain WHE 92 was used as a positive
control for bacteriocin production (Ennahar et al., 1996).
We used seven indicator microorganisms: Salmonella enterica
MIMms, Listeriamonocytogenes FMB4b, Escherichia coliVE7108,
Streptococcus pyogenes emm TYPE 77, Pseudomonas aeruginosa
FMBpa18, Staphylococcus aureus FMBDR, and Candida albicans
ATCC MYA2876. Indicator bacteria were cultivated in Brain
Heart Infusion (BHI) agar medium (Oxoid S.p.A., Milan, Italy),
supplemented with 0.3% yeast extract and 1% glucose (ygBHI),
whereas C. albicans was cultivated on Sabouraud dextrose agar
(Oxoid S.p.A., Basingstoke, UK). Three different fractions for
each Lactobacillus strain (tester bacteria) were used: (i) broth
culture at stationary growth phase, (ii) cell-free broth (obtained
by centrifugation at 10,000 × g for 10min and sterilization with
a 0.22µm syringe filter), and (iii) cell-free broth neutralized with
NaOH to pH 7.4. Sterile MRS was used as negative control. The
assay was carried out as follows: 0.1ml from an over-night culture
of the indicator strains were plated on ygBHI (or Sabouraud) agar
in order to obtain a confluent growth after incubation. Sterile
paper discs (Whatman™ Grade AA 9mm disc, Maidstone, UK)
were dipped into three different preparations from tester bacteria
and subsequently positioned on the Petri dishes inoculated with
the indicator strain. Plates were kept at 4◦C for 2 h and then
incubated at 37◦C. The presence of an inhibition halo was
checked after 24 or 48 h.
Fermentation Profile
Carbon source fermentation was determined in a 96-well
microtiter plate in a final volume of 200µl with a basal CHL
medium at pH 6.3 (Bio-Merieux, Montelieu-Vercieu, France)
containing bromocresol purple as pH indicator, and the desired
filter-sterilized carbohydrate at a final concentration of 0.5%
(w/v). The 42 different substrates tested (Supplementary Table
1) were from Sigma-Aldrich (St. Louis, MO, USA), with the
exception of fructooligosaccharides (FOS) which were from
Actilight R© (Giulio Gross S.p.A., Trezzano sul Naviglio, Italy).
Cells from an over-night culture of L. paracasei were collected
by centrifugation, washed with PBS, and used to inoculate the
liquid medium in microtiter wells (1/100 inoculation). Plates
were examined for color change (from purple to yellow) after 24
and 48 h incubation at 37◦C.
NF-κB Activation Assay
The activation nuclear factor κB (NF-κB) was studied by
means of a recombinant Caco-2 cell line stably transfected
with vector pNiFty2-Luc (InvivoGen, Labogen, Rho, Italy) as in
Taverniti et al. (2013). In brief, recombinant Caco-2 monolayers
(approximately 3 × 105 cells/well), cultivated in the presence of
50µg/ml zeocin, were washed with 0.1M Tris-HCl buffer (pH
8.0) and then incubated with 3.5 × 108 cells of L. paracasei
suspended in fresh DMEM containing 100mMHEPES (pH 7.4),
resulting in a MOI of approximately 1000. In a different set of
experiments, Caco-2 monolayers were incubated with 0.1ml of
cell-free broth obtained by centrifugation and filter-sterilization
from a stationary-phase culture of L. paracasei. Stimulation
was conducted by adding 2 ng/ml of IL-1β. After incubation at
37◦C for 4 h, the samples were treated and the bioluminescence
was measured as described by Stuknyte et al. (2011). Two
independent experiments were conducted in triplicate for each
condition.
Susceptibility to Antibiotics and Biogenic Amines
Production
The minimal inhibitory concentrations (MICs) of L. paracasei
have been determined using a micro-dilution method in LSM
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broth (ISO-Sensitest broth, Oxoid supplemented with 10% v/v
MRS Difco) as described in the ISO10932 IDF 223 document and
recommended by EFSA (2012). The data are reported as average
of two independent assays. The ability to produce cadaverine,
tyramine, histamine and putrescine respectively from L-lysine,
tyrosine disodium salt, L-histidine monohydrochloride and L-
ornithine monohydrochloride was investigated by a qualitative
test, according to the method proposed by Bover-Cid and
Holzapfel (1999). All amino acids were purchased from Sigma.
Strains were inoculated (1%) in MRS broth containing 0.1% of
each amino acid precursor and incubated at 37◦C for 18 h. The
qualitative test to evaluate decarboxylase activity was performed
in an agar medium specially formulated (0.5% tryptone, 0.5%
yeast extract, 0.5% meat extract, 0.25% NaCl, 0.05% glucose,
0.1% Tween 80, 0.02% MgSO4, 0.005% MnSO4, 0.004% FeSO4,
0.2% ammonium citrate, 0.001% thiamine, 0.2% K2PO4, 0.01%
CaCO3, 0.005% pyridoxal phosphate, 1% amino acid precursor,
0.006% bromocresol purple, 2% agar; pH 5.3). 10µL of each
culture were placed on the medium containing the same amino
acid precursor. The plates were incubated at 37◦C for 4 days.
Positive test is indicated by the color change and by aminoacid
precipitation around the corresponding spot (for tyramine only).
Human Intervention Trial
The study protocol was approved by the Research Ethics
Committee of the Università degli Studi di Milano (opinion
no. 37/12, December 2012). Written informed consent was
obtained from all subjects before recruitment. The intervention
study consisted of a randomized, double blind, cross-over pilot
trial with two parallel groups (Supplementary Figure 1). Each
volunteer was asked to participate to 6 visits: before run-in period
(visit V0); before the first treatment (V1); after the first treatment
(V2); before the second treatment (V3); after the second
treatment (V4), and at the end of the trial (V5) (Supplementary
Figure 1). After a 4-week pre-recruitment phase, volunteers have
been randomized to receive 1 capsule daily of L. paracasei LPC-
S01 (product A, 5 subjects) or L. paracasei DG (product B, 6
subjects) every day for 1 week, in addition to their habitual
diet. After a 2 week wash-out period, the volunteers received
a daily capsule of the other product for 1 week. Volunteers
received directions to keep the products at room temperature
and to avoid exposure to heat sources. Volunteers received also
oral and written instructions to consume the capsule during the
morning, while drinking natural water, at least 15min before
breakfast; alternatively, volunteers were allowed to consume
capsule in the evening at least 3 h after the last meal of the
day. The two probiotic preparations (provided by Sofar S.p.A.,
Trezzano Rosa, Italy) consisted of a gelatin capsule containing
about 24 billion viable cells of the bacterial strain L. paracaseiDG
(CNCM I-1572) and LPC-S01 (DSM 26760), respectively; silicon
dioxide and magnesium stearate were also added inside capsules
as antiagglomerants. Capsules were delivered to participants in
metal boxes sealed with a plastic cap containing desiccant salts.
From the last day of consumption of the probiotic capsules, for
the following 7 days, the volunteers provided one stool sample
per day. Furthermore, participants provided a fecal sample at
visits V1, V3, and V5 (Supplementary Figure 1). The sample
was collected in a sterile plastic pot no more than 24 h before
visit. Volunteers were asked to preserve the fecal sample at room
temperature until delivery to the laboratory, according to the
recommendations on storage conditions of intestinal microbiota
matter in metagenomic analysis provided by Cardona et al.
(2012). During the trial period, the participants compiled a
weekly diary (including a Bristol stool chart) of their bowel
habits.
Fecal DNA Extraction and qPCR
Stools were stored at −80◦C until DNA extraction, performed
by means of QIAamp DNA Stool Mini Kit (Qiagen, Valencia,
CA). Before the extraction, the sample was homogenized in
a Bead Beater Precellys 24 (Bertin Technologies, Montigny
le Bretonneux, France) after addition of 0.45 g 0.5mm glass
beads. Subsequently, the extraction proceeded consistently
with manufacturer’s recommendations. Real-Time quantitative
(qPCR) protocols were adopted for the quantification of
L. paracasei DG in fecal metagenomic DNA (targeting
the glycosyltransferase gene welF, with primers rtWELFf,
5′-TACTAAAGAAATTAGCTTTTGT-3′ and rtWELFr, 5′-
AGTAATGTCTGCATCCTCCA-3′; Ferrario et al., 2014) and
LPC-S01(targeting an hypothetical protein coding sequence
with primers qS01a-F, 5′-TGGAAGAGACCCTGCGAA-3′ and
qS01a-R, 5′-GAGGTTGATTCACAAACCGTGC-3′; this study).
These two genes were selected because they resulted unique to
the respective strain as revealed by a search in the GenBank
nucleotide database. A gradient PCR was initially performed
to standardize the qPCR conditions. qPCR amplifications were
carried out in a final volume of 15µl containing 7.5µl of
EvaGreen R© Supermix and 0.5µM of each primer. We used
100 ng of fecal DNA template in each reaction. Samples were
amplified with the following programs: for rtWELF primers,
initial hold at 95◦C for 3min, and 44 cycles at 95◦C for 30 s, 58◦C
for 30 s and 72◦C for 30 s; for qS01a primers, initial hold at 95◦C
for 3min, and 40 cycles at 95◦C for 30 s, 62◦C for 30 s and 72◦C
for 30 s. Melting curves were analyzed to confirm the specificity
of the amplification products. To generate the standard curves
with spiked feces for DG and LPC-S01 detection, a 200mg
matrix of fecal sample was added with 1× 109 bacterial cells and
DNA was extracted as reported above. Six-fold dilution series of
isolated DNA were prepared and used in qPCR reactions. The
equation of the derived standard curves was used to calculate the
correlation between Ct values and the concentration of bacterial
cells per g of feces.
Results
Comparative Genomics Revealed the Indels of
Several Chromosomal Regions in L. paracasei
LPC-S01
We generated a draft genome sequence of L. paracasei LPC-
S01 consisting of 17 contigs, which in total contained 3.02
Mbp. Comparative genomic analysis was performed on strain
LPC-S01 and the following six L. paracasei strains: the type
strain of the species (L. paracasei JCM 8130T), the probiotic
strains DG and Shirota, a strain isolated from Raschera Italian
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artisanal cheese (FMBr3), and two other L. paracasei strains
whose complete genome is available in GenBank (strains 8700:2
and N1115) (Figure 1). When we used L. paracasei LPC-S01
as reference genome in the comparative analysis, we identified
14 genomic islands with putatively known biological functions,
which have not been found in the genomes of type strain JCM
8130T or other L. paracasei strains. These chromosomal islands,
which discriminate LPC-S01 genome from the others, include
7 mobile genetic elements (e.g., prophages, phage remnants,
and integrated plasmids; Figure 1), a transposon containing
a phospho-β-galactosidase operon (region “a” in Figure 1;
Figure 2A), a putative taurine transport and metabolization
operon (b; Figure 2B), a large sugars transport/metabolization
island (c; Figure 2C), an ABC-type Fe3+ transport system (d;
Figure 2D), and a putative nucleotide transport and metabolism
operon (e; Figure 2E). We also found in the genome of strain
LPC-S01 two regions putatively involved in exopolysaccharide
(EPS) synthesis. Specifically, one of these EPS regions (namely,
EPS2; Figure 1) was found exclusively in the genome of L.
paracasei LPC-S01 and is constituted of 14 putative genes,
including six genes potentially coding for glycosyl transferases.
Notably, BLASTN search revealed inside EPS2 a region of about
8 kb encompassing eight putative genes, which did not find any
significant match in the GenBank database (genes from A to H
in Figure 3). In subsequent comparative analyses, we used the
genome of the other L. paracasei strains as reference to identify
missing chromosomal islands in the genome of strain LPC-S01.
Largely most of the genomic regions that are absent in LPC-
S01 genome refer to mobile genetic elements, DNA restriction-
modification systems, and EPS biosynthesis regions (data not
shown).
In vitro Assays Showed That L. paracasei
LPC-S01possesses Marked Acid Tolerance and
Noticeable Adhesion Ability
The probiotic potential of strain L. paracasei LPC-S01 was
assessed through in vitro experiments including L. paracasei
DG and L. paracasei Shirota as reference probiotic strains.
The potential ability to survive the gastro-intestinal transit
was assessed in simulated gastric juices at pH 3 or 2 (90min
incubation), followed by 3 h incubation in bile (Oxgall) solution.
All strains showed high tolerance to pH 3; cell viability, in fact,
was not significantly reduced after 4.5 h (Supplementary Figure
2). Conversely, pH 2 determined a drastic reduction of the
viability of all tested strains (Figure 4). However, L. paracasei
LPC-S01 displayed the highest tolerance, which was significantly
higher than that of the reference strain L. paracasei Shirota
(Figure 4).
Growing concentrations of Oxgall were added to the MRS
broth to assess the ability to grow in presence of bile. For all tested
FIGURE 1 | Comparative genomic analysis of Lactobacillus paracasei LPC-S01 (reference genome) with the genome sequences of other six L.
paracasei strains. Gray rectangles indicate mobile genetic elements. pϕ, prophage-related regions. mge, mobile genetic element; mge 1, putative integrated
plasmid; mge 2, putative mobile genetic element containing a restriction-modification system. EPS, putative exopolysaccharide coding operon. Letters flanking red
rectangles refers to panels of Figure 2.
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FIGURE 2 | In silico predicted functional organization of the chromosomal regions of Lactobacillus paracasei LPS-S01 that discriminates LPC-S01
from the others strains included in the comparative genomic analysis depicted in Figure 1. Letters in the panels of this figure refer to the letters flanking red
(Continued)
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FIGURE 2 | Continued
rectangles in Figure 1. (A) Putative phospho-β-galactosidase operon. In black are indicated transposase-associated putative genes. In white are indicated putative
genes that are also present in the genome of the other L. paracasei strains considered for comparative genomic analysis. (B) Putative taurine ABC-type transport and
metabolization operon. (C) Multi-transport region for the uptake of sugars and other small molecules. The membrane transport mechanism is indicated above the
picture, whereas the transported molecule is indicated below. ABC, ATP binding cassette transport system, PTS, phosphotransferase transport system. Gal-NAc,
N-acetyl galactosamine; Glu-NAc, N-acetyl glucosamine; Co+, cobalt ions. (D) Putative ABC-type Fe3+ transport system. Gene “a,” putative acetyltransferase
(COG0456) coding gene; gene “b,” putative gene coding for an uncharacterized protein (DegV family, COG1307). (E) Putative nucleotide transport and metabolism
operon. MFS, major facilitator superfamily. In white are indicated putative genes that are also present in the genome of all the other L. paracasei strains considered.
FIGURE 3 | BLASTN search results for the region EPS2 from Lactobacillus paracasei LPC-S01, which putatively codes for the enzymes involved in the
synthesis of an exopolysaccharide (EPS). The figure has been obtained adding a picture of the putative EPS operon over the graphic representation of the
BLASTN output. In white are indicated genes outside the putative EPS operon.
strains, we observed a dose-dependent inhibition of the bacterial
growth, which was completely arrested at Oxgall concentrations
higher than 1%. In specific, Shirota displayed the best tolerance
to bile, even though not statistically significant (Supplementary
Figure 3).
Subsequently, the ability of bacterial strains to adhere to the
Caco-2 epithelial cell layer was tested. Only LPC-S01 displayed
a marked adhesive phenotype, corresponding to an adhesion
index (i.e., bacterial cells per 100 Caco-2 cells) of more than
2000 (Figure 5A). Also strain DG displayed adhesion ability,
whereas strain Shirota was unable to adhere on Caco-2 cells, as
observed in previous studies (Botes et al., 2008; Guglielmetti et al.,
2008).
Caco-2 cell layer was also used to explore the
immunomodulatory properties of L. paracasei strains by
testing the effect of the microorganisms on NF-κB activation
in presence of the pro-inflammatory cytokine IL-1β. To this
aim, we employed a reporter cell line obtained by transfecting
Caco-2 cells with a luciferase reporter vector induced by active
NF-κB (Guglielmetti et al., 2010a). For all three L. paracasei
strains, both bacterial cells and cell-free neutralized broths
were able to significantly decrease the NF-κB-dependent
production of bioluminescence. Particularly, we found that
the highest ability to reduce NF-κB activation was exerted
by DG and LPC-S01 cells, and by broth from Shirota culture
(Figure 5B).
We also tested the ability of the bacteria under investigation to
produce inhibitor molecules against pathogens by disc diffusion
assay carried out by using cell-free MRS broths cultures.
With the only exception of L. plantarum WHE 92 against
L. monocytogenes, none of the neutralized broths was able to
prevent pathogens’ growth, suggesting that, plausibly, the only
inhibitory molecules produced by tested L. paracasei strains were
organic acids (Data not shown).
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FIGURE 4 | Tolerance of Lactobacillus paracasei strains to simulated
gastric juice at pH 2 (90min incubation) and bile (180min incubation).
Dashed lines refer to controls (i.e., bacterial cells incubated in phosphate
buffer, pH 6.5). Data are reported as the number of viable bacterial cells (CFU)
plotted on a semi-logarithmic diagram. Vertical bars at each point refer to
standard deviation calculated on three independent experiments conducted in
duplicate. Asterisk between strain LPC-S01 and Shirota at the end of the
experiment indicates statistically significant difference according to two-tailed
unpaired Student’s t test (*P < 0.05).
Afterwards, the in vitro probiotic properties of LPC-S01
and reference strains were assessed by testing their ability
to produce acid from 44 different carbohydrate sources.
The fermentation patterns of L. paracasei strains were very
similar. In detail, the three tested strains fermented cellobiose,
FOS, fructose, galactose, glucose, inulin, maltulose, mannitol,
mannose, ribose, salicine, sorbose, sucrose, trehalose, and
turanose (Supplementary Table 1).
In conclusion, the in vitro experiments carried out in this
study showed that strain L. paracasei LPC-S01 possesses potential
probiotic capabilities to be oral administered comparable to
those of the probiotic commercial strains L. paracasei DG and
Shirota. Notably, the survival rate of LPC-S01 to simulated
gastrointestinal transit at pH 2 was significantly higher than
that of the reference probiotic strain Shirota; in addition, strain
LPC-S01 displayed marked adhesion ability, corresponding to an
adhesion index higher than 2000.
We also studied the antibiotic resistance of L. paracasei LPC-
S01by the microdilution assay recommended by International
Organization for Standardization (ISO, 2010) with reference
to the EFSA breakpoints for L. casei/paracasei (EFSA, 2012).
The MICs for strain LPC-S01 was below the breakpoints
for all tested antibiotics (Table 1). Finally, the safety of
L. paracasei strains was also estimated by assessing the
bacterial decarboxylation of amino acids, which generates
biogenic amines in food (Deepika Priyadarshani and Rakshit,
2014). According to our experiments, none of the tested L.
paracasei strains produced histamine, tyramine, putrescine and
cadaverine (Data not shown), which are among the most
common biogenic amines found in food products (Naila et al.,
2010).
L. paracasei LPC-S01 Persists in the Gut of
Healthy Adults
The ability of L. paracasei LPC-S01 to colonize the human
gastrointestinal tract was tested with a pilot intervention trial
based on a double-blind, randomized, cross-over design, in
comparison with the probiotic strain L. paracasei DG. We
enrolled 11 healthy adult volunteers, who were asked to consume
for 1 week a capsule per day containing LPC-S01 or DG cells.
Out of 11 enrolled volunteers, 8 concluded the study. Three
volunteers dropped out of the study due to non-conformity
(n = 1) and protocol violation (missed probiotic consumption;
n = 2) (Supplementary Figure 1). Capsules, which contained
about 24 billion CFU of L. paracasei, were well tolerated by
all participants and no adverse events were reported. In order
to quantify L. paracasei cells in the fecal samples all over the
trial, we used qPCR with primers targeting gene welF (specific
for strain DG; Ferrario et al., 2014) and a gene coding for
a hypothetical protein (specific for strain LPC-S01; primers
designed in this study). According to repeated measure ANOVA,
we did not find significant difference in the persistence of the two
L. paracasei strains (Figure 6). Specifically, the concentrations
of LPC-S01 and DG cells were above the qPCR detection limits
for an average of 5 days from the end of treatment; in addition,
L. paracasei cells were not detectable in the fecal samples
after 7 ± 2 evacuations from the last capsule consumption
(Figure 6A).
Discussion
Bacterial vaginosis (BV) is one of the most common urogenital
diseases affecting women of reproductive age (Allsworth and
Peipert, 2007). BV is typically associated to the disruption of
the healthy vaginal microbiota, which is normally dominated
by lactobacilli (Ma et al., 2012). Due to the dominant role of
dysbiosis in the onset of BV, probiotics, which are regularly used
to prevent and treat dysbiosis in the intestine, have been proposed
as a strategy to cure this urogenital condition and reduce its
recurrence (Bodean et al., 2013). Several studies documented
the beneficial effects on BV of viable Lactobacillus cells directly
introduced in the vagina as suppository (Patel et al., 2008;
Donders et al., 2010). Nonetheless, also the oral administration
of probiotics has been demonstrated to be an efficient strategy
to alleviate BV symptoms and prevent recurrence (Reid, 2006;
Bodean et al., 2013). In fact, it was proposed that ingested
lactobacilli, similarly to colonic pathogenic bacteria, once
excreted from rectum, may ascend to the vagina through
perineum (Reid et al., 2001; Bastani et al., 2012). Then, once
in the vagina, lactobacilli create a protecting barrier against the
translocation from the gut of possible detrimental bacteria such
as Prevotella spp. or E. coli, and, at the same time, limit the
possible migration of uropathogens from vagina to the bladder
(Reid et al., 2001).
The oral administration of probiotics is a more practical
route than their direct introduction in the vagina, and can
also provide consumers with the gastrointestinal health benefits
typically associated with the consumption per os. In this context,
this study aimed to the identification of a probiotic strain
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FIGURE 5 | Experiments on human epithelial colorectal Caco-2 cell layer. (A) Adhesion of Lactobacillus paracasei strains to the Caco-2 epithelial cell layer as
observed with Giemsa staining under a light microscope. Bars, 25µm. One Caco-2 nucleus for each layer is indicated with the letter N. LPC-S01 adhesion was
specific to Caco-2 cells: no adhesion was detected on the cover glass underlying Caco-2 cells (G; top part of the panel on the left). (B) Effect of L. paracasei strains
on Caco-2 cells stably transfected with an NF-κB/luciferase reporter vector, in the presence of 5 ng/ml of IL-1β. Data in the histograms are the means (± standard
deviations) from two independent experiments conducted in triplicate. RLU, relative luminescence units. Asterisks indicate statistically significant differences according
to two-tailed unpaired Student’s t-test: ***P < 0.001; **P < 0.01; *P < 0.05.
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TABLE 1 | Antibiotic sensitivity of Lactobacillus paracasei LPC-S01
determined according to the microdilution assay recommended by EFSA
(2012).
EFSA breakpoint LPC-S01
Ampicillin 2 2
Vancomycin not required >256
Gentamicin 32 32
Kanamycin 64 32
Streptomycin Not required 32
Erythromycin 1 0.5
Clindamycin 1 0.062
Tetracycline 4 2
Chloramphenicol 4 4
Amoxicillin Not indicated 1
Data are reported as the lower concentration (mg/l) inhibiting bacterial growth (minimal
inhibitory concentration, MIC).
possessing a wide range of properties, which may support its
(i) industrial production, (ii) gastrointestinal administration, and
(iii) vaginal colonization. To this aim, we focused our attention
on Lactobacillus paracasei, a species characterized by marked
ecological flexibility and extensive genetic diversity, which is
widely used in industry (Cai et al., 2007). Particularly, we
studied strain L. paracasei LPC-S01, which was originally isolated
from the vagina of a healthy adult and has had a several-years
history of commercial use as a vaginal probiotic for topical
application in Europe. Specifically, the experiments carried out
in this study were designed to evaluate if L. paracasei LPC-
S01 has probiotic properties that can support its administration
per os.
At first, the draft genome of LPC-S01 was analyzed by
comparative genomics. We found the presence of numerous
accessory genes (i.e., unique to this particular strain) that
suggests the niche-generalists nature of LPC-S01; such potential
ability to adapt to a wide range of environmental conditions is
evidenced, for instance, by the presence of large chromosomal
regions including genes for the utilization of numerous sugars
(Figure 2C). Similar regions are also present in the genome
of the probiotic strains DG and Shirota, which are of human
intestinal origin. On the contrary, it was proposed that the
adaptation of L. paracasei to the nutrient-rich milk environment
had been gone along with extensive decay of genes involved in
carbohydrate utilization (Broadbent et al., 2012). Accordingly,
we found the lack of genes for sugar transport and metabolism
in the chromosome of the dairy strains L. paracasei FMBr3
and N1115 compared to LPC-S01, DG, and Shirota strains
(Figure 1).
The in vitro characterization of L. paracasei LPC-S01 was
conducted in accordance with a procedure conventionally used
to predict the probiotic potential of a microbial strain; such
process consists in the assessment of sensitivity to acidity and
bile, adhesion ability, pathogen inhibition, sugar fermentation
profile, and immunomodulatory properties. In order to better
predict the probiotic capabilities of LPC-S01, the reference
strains Shirota and DG were also included in the study.
L. paracasei Shirota is one of the most intensively studied
probiotics (van den Nieuwboer et al., 2015; Wang et al.,
2015) that has been used in the production of the fermented
milk Yakult since 1935. L. paracasei DG is a bacterial strain
with demonstrated probiotic properties (D’Incà et al., 2011;
Tursi et al., 2013; Ferrario et al., 2014), which is included in
Enterolactis R©, one the most popular probiotic supplements in
Italy. We observed that the in vitro performances of LPC-S01
were basically very similar to those of the reference strains.
One exception was the significantly higher ability of LPC-
S01 to survive in simulated gastric juice at pH 2 compared
to L. paracasei Shirota, which is an acid-tolerant bacterial
strain with demonstrated survivability to human gastrointestinal
transit (Tuohy et al., 2007; Wang et al., 2015). In addition,
LPC-S01 showed a much higher ability to adhere to Caco-2
epithelial cell layer than DG and Shirota. Bacterial adhesion
properties mainly depend on the molecules exposed at the
external cell surface (Guglielmetti et al., 2008; Polak-Berecka
et al., 2014). Genome analysis revealed the presence in LPC-S01
of putative exopolysaccharide coding region (EPS2) containing
a cluster of five genes which are not present in the other
known L. paracasei genomes. Therefore, EPS2 could potentially
support the synthesis of a peculiar exopolysaccharide molecule,
which could plausibly contribute to the adhesion ability of the
LPC-S01. Exopolysaccharides have been proposed to promote
Lactobacillus adhesion (Ren et al., 2014), although, more
frequently, the presence of a polysaccharide capsule has been
shown to reduce adhesion by masking cell surface Lactobacillus
adhesins determinants (Lebeer et al., 2012; Horn et al., 2013;
Dertli et al., 2015), which are most commonly proteins (Lebeer
et al., 2012; Polak-Berecka et al., 2014), (lipo)teichoic acids
(Granato et al., 1999), and/or fatty acids (Polak-Berecka et al.,
2014).
The acid tolerance and adhesion properties of LPC-S01
suggest that this bacterium might tolerate and adapt to
the gastrointestinal environment. To test this hypothesis, we
performed an intervention trial, in which we compared the
gut persistence of L. paracasei LPC-S01 with that of strain
DG. Following a daily consumption of 24 billion viable cells
for 1 week, we estimated that strain LPC-S01 reached a
concentration of about 108 cells per g of feces, persisting
above the detection limit (105 cells per g of feces) for about
5 days, which is not significantly dissimilar to the persistence
of the reference L. paracasei DG, a strain demonstrated to
colonize the human gut of healthy adults and induce specific
modifications in the microbiota composition (De Vecchi et al.,
2008; Ferrario et al., 2014). Our data on L. paracasei persistence
are in agreement with other studies, which observed that
the persistence of L. paracasei Shirota in the gastrointestinal
tract of healthy adults is lower than 1 week after cessation
of the probiotic ingestion (Tuohy et al., 2007; Wang et al.,
2015). The persistence of a certain probiotic strain in the
gut plausibly depends on the evacuation frequency. In our
study, we found persistence of strains LPC-S01 and DG as
average for 7 evacuations. No data correlating the day of
persistence with the number of evacuations were found in
literature.
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FIGURE 6 | Persistence of Lactobacillus paracasei in the gastrointestinal tract of healthy adults. (A) Bacterial concentration of L. paracasei DG and
LPC-S01 in the fecal samples collected during the study per single participant. (B) Average change in the fecal concentration of L. paracasei cells after the
probiotic-intake period. Vertical bars denote 0.95 confidence intervals. Current effect according to repeated measures ANOVA performed to determine the statistical
significance of the treatment × time interaction: F(5, 65) = 0.794; p = 0.558.
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Conclusions
The results of this study can be summarized as follows:
(i) according to comparative genomic analysis, L. paracasei
LPC-S01 possesses the genetic features of a niche-generalist
member of its species;
(ii) in vitro tests evidenced that the probiotic properties of strain
LPC-S01, with respect to those of the well-known probiotic
references L. paracasei Shirota and DG, are equal for the bile
tolerance and the reduction of NF-κB activation in Caco-
2 cells, or superior for the tolerance to gastric juice and
the adhesion to Caco-2 epithelial cells (Shirota is unable to
adhere on Caco-2-cells);
(iii) L. paracasei LPC-S01 is a safe bacterial strain for human
consumption, which does not contain any acquired
antibiotic resistance, does not produce biogenic
amines and can be administered in high number
(24 billion CFU) to healthy people without adverse
events;
(iv) when administered as capsule containing 24 billion CFU, L.
paracasei LPC-S01 transiently colonizes the gastrointestinal
tract of the host, persisting for at least 5 days after
the end of a 7-days oral consumption (corresponding to
about 7 evacuations) and therefore displaying colonizing
performances not dissimilar to those of the probiotic
commercial strain L. paracasei DG.
In conclusion, this study demonstrates that the vaginal isolate
L. paracasei LPC-S01 possesses safety and functional properties
that may support its use as probiotic to be administered per os
for potential intestinal as well as vaginal applications. In this
perspective, it would be of interest to carry out a clinical trial
consisting of the oral administration to healthy adult women
of L. paracasei LPC-S01 cells, in order to verify the potential
ability of this probiotic bacterium to (i) modulate the intestinal
and vaginal microbiota, and (ii) colonize the human vagina via
gastrointestinal route.
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